This update will be presented as part of the OPERA-01 trial-in-progress poster at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago, Illinois.

Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting –Favorable safety and tolerability ...

We’re giving away an exclusive FREE glossy poster of the iconic moment Liverpool ... What does PSG’s first ever Champions League title mean for the club? Christian and Stefano then talk ...

Adam Sandler has starred in dozens of comedies, but most of his best films released in the back half of the '90s. Despite being responsible for some of the most beloved comedy movies of the past ...

LaSalle’s Gil Maure Park once again became the hub for anglers and families this May as the 16th Annual Detroit River Walleye Classic took place on the first Saturday of the month. Hosted by the ...

(WNKY) – The inaugural Old Get Together celebration transformed the historic Potter ... vendors like Spencer’s Coffee and Cassady’s Real Smoke. Despite being its first year, the celebration exceeded ...

Speaking in front of the Georgian Parliament on Independence Day, former President Salome Zurabishvili stressed the need to prioritize parliamentary elections—followed by local elections or held ...

The blessed and brightest in our little sliver of the musical universe—from OGs, current day killas, and cats on the come-up—together fill ... strange sojourn to get blessed down at the ...

today announced that a Trial in Progress poster for its first-in-human, Phase 1/2 study of its first-in-class oral DHX9 inhibitor, ATX-559, will be presented at the 2025 American Society of Clinical ...

ATX-559, a first ... poster for its first-in-human, Phase 1/2 study of its first-in-class oral DHX9 inhibitor, ATX-559, will be presented at the 2025 American Society of Clinical Oncology Annual ...

today announced that a Trial in Progress poster for its first-in-human, Phase 1/2 study of its first-in-class oral DHX9 inhibitor, ATX-559, will be presented at the 2025 American Society of ...